(Q34966036)

5 August 2017

1 reference

title

Pegylated interferons for the treatment of chronic hepatitis C infection (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

Bruce A Luxon

1

1 reference

5 August 2017

Michael Grace

series ordinal

2

1 reference

5 August 2017

Diana Brassard

series ordinal

3

1 reference

5 August 2017

Ronald Bordens

series ordinal

4

1 reference

5 August 2017

language of work or name

1 reference

1 September 2002

1 reference

5 August 2017

published in

Clinical Therapeutics

1 reference

5 August 2017

volume

24

1 reference

5 August 2017

issue

9

1 reference

5 August 2017

page(s)

1363-1383

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Humans as the world's greatest evolutionary force

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Pathogenesis, diagnosis and management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

The hepatitis C virus: Overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency scid)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Biomedical and biotechnological applications of PEG- and PM-modified proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Site-directed polyethylene glycol modification of trichosanthin: effects on its biological activities, pharmacokinetics, and antigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

In HIV-1-infected patients, plasma levels of HIV-1 RNA are inversely correlated with IFN-alpha responsiveness of whole-blood cultures to sendai virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980042-X

7 January 2021

10.1016/S0149-2918(02)80042-X

Identifiers

DOI

1 reference

5 August 2017

1 reference